Navigation Links
Merck/Schering-Plough's Zetia and Vytorin Have Lost Substantial Patient Share in Second- and Third-Line Therapy Since Last Year's Analysis of Dyslipidemia
Date:8/12/2009

WALTHAM, Mass., Aug. 12 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that Merck/Schering-Plough's Zetia and Vytorin have lost substantial patient share in second- and third-line therapy since last year's analysis of the dyslipidemia drug market. This decline is most likely attributed to the publication of the ENHANCE trial which called into question the ability of these agents to improve clinical outcomes beyond the ability of statin monotherapy.

The new Treatment Algorithms in Dyslipidemia report also finds that statins have gained patient share with Zetia's and Vytorin's decline in use since the ENHANCE fallout. Survey results indicate that over the next two years cardiologists and primary care physicians intend to be more aggressive in their treatment of dyslipidemia. They also plan to increase their use of the most potent statins, particularly Pfizer's Lipitor and AstraZeneca's Crestor, and adjunct agents belonging to the classes of fenofibrates and bile acid sequestrants.

"Our survey of physicians indicates that favorable results from the 2008 JUPITER trial are likely to increase the percentage of physicians prescribing Crestor in the first line and may lead to increases in Crestor's patient share. However, Crestor will have to compete with the availability of generic Lipitor in 2011 and AstraZeneca should try to gain as much traction as possible prior to the arrival of this additional competition," stated Amanda Puffer, M.Sc., analyst at Decision Resources.

By combining patient-level claims data with physician survey data, this report can be used to build patient-flow models and analyze the assumptions driving these models.

'/>"/>

SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. HCM Announces Substantial Growth in 2007
2. Excalibur Celebrates PIramed Sale With Substantial Cash Return to Investors
3. BioElectronics Corporation - Substantial International Expansion Producing Sustained Revenue Growth-Company Reaches Monthly Break Even
4. KJT Group Positions for Substantial Growth
5. Gerresheimer Substantially Increases Quarterly Operating Profit
6. Following a Record Year in 2008 Gerresheimer Again Sets its Sights on Substantial Growth in 2009
7. Studies Presented at International Conference on Alzheimers Disease Reveal Substantial Economic Costs and Caregiver Burden Associated with Alzheimers Disease
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
10. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
11. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... January 22, 2015 Crystal Diagnostics (CDx) Xpress ... it has received AOAC-PTM Certifications for the six non-O157 Shiga ... O145; collectively referred to as STEC or the “Big-6”) as ... forming unit (cfu) per 325 g of raw ground beef ...
(Date:1/22/2015)... zFlo Motion , a US leader in biomechanics software ... a new partner. STT-Systems has developed an impressive ... with offerings in the optical-motion capture, 3D scanning, and industrial ... unit), iSen, is opening eyes around the world. With no ...
(Date:1/22/2015)... Wilmington, DE (PRWEB) January 22, 2015 ... the Pistoia Alliance, which helps companies check the legal ... set to expand to China. , As their ... companies are globally adopting software solutions built as a ...
(Date:1/22/2015)... Diagenode, Inc., a leading global ... and complete solutions for epigenetics research, recently launched ... the need for manual processing. The new ChIPettor ... of histones or transcription factors and a semi-automated ...
Breaking Biology Technology:Crystal Diagnostics Awarded AOAC-PTM Accreditation for the Rapid Detection of “Big 6” E.coli Food Pathogens 23D Motion Capture Just Got Easy 2Global Compliance Service for Controlled Substances to Expand to China 2Diagenode Launches Unique Semi-Automated Solution for Chromatin Immunoprecipitation 2
... Nventa Biopharmaceuticals,Corporation (TSX: NVN) today announced financial results for ... and highlighted several,recent product developments and corporate milestones., ... Recent product and corporate highlights:, o ... it will initiate a ...
... Risks of Progression of,Vertebral Fracture in US-Caucasian Women, ... (Amex: ILI ), announced today that Nazneen ... Development, will present new research,findings on the genetics ... the,American Society of Human Genetics, which takes place ...
... LLC, a privately-held,biopharmaceutical company focused on developing novel ... Sindbis viral vector, announced today,that it has appointed ... immediately, to lead the company,s next phase of ... Stonebanks will serve on Cynvec,s Board,of Directors., ...
Cached Biology Technology:Nventa Biopharmaceuticals Announces Third Quarter 2008 Financial Results and Recent Corporate Highlights 2Nventa Biopharmaceuticals Announces Third Quarter 2008 Financial Results and Recent Corporate Highlights 3Nventa Biopharmaceuticals Announces Third Quarter 2008 Financial Results and Recent Corporate Highlights 4Nventa Biopharmaceuticals Announces Third Quarter 2008 Financial Results and Recent Corporate Highlights 5Nventa Biopharmaceuticals Announces Third Quarter 2008 Financial Results and Recent Corporate Highlights 6Nventa Biopharmaceuticals Announces Third Quarter 2008 Financial Results and Recent Corporate Highlights 7Interleukin Genetics to Present New Findings on Osteoporosis at the 58th Annual Meeting of the American Society of Human Genetics 2Interleukin Genetics to Present New Findings on Osteoporosis at the 58th Annual Meeting of the American Society of Human Genetics 3Cynvec LLC(SM) Appoints Former Johnson & Johnson Executive Frank D. Stonebanks as President and Chief Executive Officer 2Cynvec LLC(SM) Appoints Former Johnson & Johnson Executive Frank D. Stonebanks as President and Chief Executive Officer 3
(Date:1/22/2015)... Jan. 13, 2015 /PRNewswire/ - Today, FindBiometrics, the leading source of ... of its new website design. "When we launched ... says Peter O,Neill , founder and CEO of FindBiometrics. ... needs involvement from the key players on a very broad ...
(Date:1/22/2015)... Jan. 15, 2015  BellBrook Labs, a leader in ... the launch of a TR-FRET (time resolved Forster ... UDP Assay, a high throughput screening assay for ... will allow for sensitive detection of hundreds of ...
(Date:1/22/2015)... Washington , January 20, 2015 Investorideas.com, ... tech stocks, releases video from the CES 2015 (Consumer Electronics ... Apollo Robbins . Apollo shows how easily ... smart wallet, a product of NXT-ID, Inc. (NASDAQ: ...
Breaking Biology News(10 mins):Identity Industry Leading Publication Debuts New Look As Biometrics Hit Mainstream 2BellBrook Labs Launches a High Throughput Screening Assay for Glycosyltransferases with TR-FRET Readout 2Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 2Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 3
... red wormlike insects that nibble on the plant's leaves ... larvae that survive eventually evolve methods to overcome plant ... trying to thwart the insect have identified Hessian fly ... itself from the munching larvae. The researchers report their ...
... target organs or cell types, you need a good ... the target in question could do the trick. , ... tiny capsules require preorganized structures or "molds" to shape ... synthetic or purification procedure. Korean researchers led by Kimoon ...
... have discovered how cells fine-tune their oxygen use to make ... Too little oxygen threatens life by compromising mitochondria that power ... by replacing one protein with an energy-efficient substitute that "is ... begins to run out of gas," says Gregg Semenza, M.D., ...
Cached Biology News:Scientists find genes involved in the battle between Hessian flies and wheat 2Scientists find genes involved in the battle between Hessian flies and wheat 3Navigable nanotransport 2Need oxygen? Cells know how to spend and save 2
... of 3 siRNAs specifically targeted to your ... product. The siTrio reagent guarantees you get ... gene when used under standard conditions (100 ... optimal transfection with one of B-Bridges controls). ...
... siTrio siRNA --- a cocktail of 3 ... of interestis our most popular product. The ... 75% knockdown of your target gene when ... for transfection and confirmation of optimal transfection ...
... has improved stability and convenience from the former ... has overcome this problem but also produced some ... the formulation of HRP conjugated antibody from lyophilized ... change, the stability of the conjugate has improved ...
... multi-purpose, high gel-strength agarose suitable for a ... conventional constant field to Pulsed Field Gel ... strength and exclusion limits, Multi ABgarose can ... running times. This in turn means reduced ...
Biology Products: